Matthias von Herrath, MD, is vice president of Novo Nordisk’s type 1
diabetes team at the company’s Seattle research center. Matthias leads
a diabetes translational unit, which is based on less conventional and
innovative design for immune-based interventions.
Matthias von Herrath, MD, Vice President of Novo Nordisk’s Diabetes R&D Center in Seattle, is one of the researchers featured in the GOBOLDLY campaign from the biopharmaceutical industry group, PhRMA.